Affymax, Inc. (AFFY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Affymax, Inc. (AFFY) with AI Score 54/100 (Hold). Affymax, Inc. is a biotechnology company based in New York City that was founded in 2001. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Affymax, Inc. (AFFY) Healthcare & Pipeline Overview
Affymax, Inc., a biotechnology company with a history of drug development for critical conditions, currently lacks significant operational activity. Based in New York, the company's past focus on innovative treatments contrasts with its present dormant state, reflecting the high-risk, high-reward nature of the biotechnology sector.
Investment Thesis
Affymax, Inc. presents a challenging investment case due to its current lack of significant operations and a negative profit margin of -1053.6%. The company's high beta of 8.28 indicates extreme volatility, making it a speculative investment. While its gross margin stands at 99.1%, this is misleading given the absence of substantial revenue generation. A potential catalyst could be a strategic pivot or acquisition, but this remains highly uncertain. Investors should carefully consider the risks associated with OTC-listed companies, including limited liquidity and disclosure. The company's future prospects depend on its ability to redefine its business strategy and secure funding for new ventures. Given the current financials and operational status, Affymax, Inc. carries a high degree of risk.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a very small or non-existent valuation.
- Negative P/E ratio of -0.00 reflects the company's lack of profitability.
- Profit margin of -1053.6% demonstrates significant losses relative to revenue.
- Gross margin of 99.1% suggests high potential profitability if the company can generate substantial revenue.
- Beta of 8.28 indicates high volatility compared to the market.
Competitors & Peers
Strengths
- Previous experience in drug development.
- Potential intellectual property assets.
- Established presence in the biotechnology sector.
- Experienced management team.
Weaknesses
- Lack of significant operations.
- Negative profit margin.
- High beta indicating volatility.
- Limited financial resources.
Catalysts
- Upcoming: Potential strategic acquisition or merger.
- Upcoming: Licensing or partnership agreements.
- Upcoming: Repurposing existing assets.
- Upcoming: Shift in focus to orphan drugs.
- Upcoming: Investment in novel technologies.
Risks
- Ongoing: Lack of significant operations.
- Ongoing: Negative profit margin.
- Potential: Competition from established pharmaceutical companies.
- Potential: Regulatory hurdles and approval processes.
- Potential: Clinical trial failures.
Growth Opportunities
- Strategic Acquisition or Merger: Affymax, Inc. could seek a strategic acquisition or merger with another biotechnology company to leverage its existing assets or intellectual property. This could provide a pathway for the company to re-enter the market with a new focus and access to additional resources. The timeline for such a transaction is uncertain, but it could potentially occur within the next 1-2 years, depending on market conditions and the company's ability to identify a suitable partner. The market size for mergers and acquisitions in the biotechnology sector is substantial, with billions of dollars in deals occurring annually.
- Licensing or Partnership Agreements: Affymax, Inc. could pursue licensing or partnership agreements with other pharmaceutical or biotechnology companies to develop and commercialize new drugs or technologies. This would allow the company to generate revenue and share the risks and costs associated with drug development. The timeline for such agreements could vary depending on the specific opportunity, but it could potentially occur within the next 6-12 months. The market for licensing and partnership agreements in the biotechnology sector is significant, with numerous deals occurring each year.
- Repurposing Existing Assets: Affymax, Inc. could explore the possibility of repurposing its existing assets or intellectual property for new applications or indications. This could involve identifying new uses for previously developed drugs or technologies, or adapting them for use in different therapeutic areas. The timeline for repurposing existing assets could vary depending on the specific opportunity, but it could potentially occur within the next 12-18 months. The market for repurposed drugs is growing, as companies seek to leverage existing assets to address unmet medical needs.
- Focus on Orphan Drugs: Affymax, Inc. could shift its focus to the development of orphan drugs for rare diseases. This would allow the company to target niche markets with less competition and potentially receive expedited regulatory review and approval. The timeline for developing orphan drugs could vary depending on the specific disease and the stage of development, but it could potentially occur within the next 3-5 years. The market for orphan drugs is growing rapidly, as companies recognize the potential for high returns and the opportunity to address unmet medical needs.
- Investment in Novel Technologies: Affymax, Inc. could invest in novel technologies, such as gene therapy or personalized medicine, to develop innovative treatments for serious diseases. This would require significant capital investment and a long-term commitment to research and development. The timeline for developing novel technologies could vary depending on the specific technology and the stage of development, but it could potentially occur within the next 5-10 years. The market for gene therapy and personalized medicine is growing rapidly, as these technologies hold the promise of revolutionizing healthcare.
Opportunities
- Strategic acquisition or merger.
- Licensing or partnership agreements.
- Repurposing existing assets.
- Focus on orphan drugs.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and approval processes.
- Clinical trial failures.
- Funding constraints.
Competitive Advantages
- Potential intellectual property from previous drug development efforts.
- Established presence in the biotechnology sector.
- Experienced management team (though currently only two employees).
About AFFY
Affymax, Inc. was founded in 2001 with the goal of developing drugs to treat serious and often life-threatening conditions. The company aimed to address unmet medical needs through innovative therapies. Based in New York City, Affymax, Inc. operated within the biotechnology sector, focusing on research and development of pharmaceutical products. However, as of the current date, Affymax, Inc. does not have significant operations. The company's previous activities centered around the development of novel treatments, indicating a commitment to advancing healthcare solutions. Despite its initial focus, Affymax, Inc.'s current state reflects a period of inactivity, suggesting potential challenges in bringing its products to market or a strategic shift in its business direction. The company's history highlights the dynamic and often volatile nature of the biotechnology industry, where companies may face significant hurdles in drug development, regulatory approvals, and commercialization. The company's evolution from an active drug developer to a company without significant operations underscores the risks associated with the biotechnology sector, including clinical trial failures, funding constraints, and competitive pressures. The company's past efforts in developing drugs for serious conditions reflect its initial ambition to contribute to advancements in medical treatments. The company's current lack of operations suggests a need for strategic reevaluation or restructuring to revitalize its business activities.
What They Do
- Previously developed drugs for serious and life-threatening conditions.
- Focused on research and development of pharmaceutical products.
- Aimed to address unmet medical needs through innovative therapies.
- Operated within the biotechnology sector.
- Based in New York City.
- Currently does not have significant operations.
Business Model
- Historically focused on developing and commercializing pharmaceutical products.
- Aimed to generate revenue through the sale of its drugs.
- Relied on research and development to create innovative therapies.
Industry Context
Affymax, Inc. operates within the biotechnology industry, a sector characterized by high risk and high reward. The industry is driven by innovation in drug development and medical technology, with companies constantly seeking to address unmet medical needs. The competitive landscape includes established pharmaceutical giants and smaller, specialized biotech firms. Affymax, Inc.'s current lack of operations positions it as an outlier in the industry, as most active biotech companies are engaged in research, clinical trials, or commercialization of products. The biotechnology industry is subject to stringent regulatory oversight and requires significant capital investment.
Key Customers
- Historically targeted patients with serious and life-threatening conditions.
- Aimed to serve healthcare providers and hospitals.
- Sought to provide treatments for unmet medical needs.
Financials
Chart & Info
Affymax, Inc. (AFFY) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Friday
· Jan 17, 2020
-
Stocks That Hit 52-Week Highs On Thursday
· Jan 16, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AFFY.
Price Targets
Wall Street price target analysis for AFFY.
MoonshotScore
What does this score mean?
The MoonshotScore rates AFFY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jonathan Couchman
Managing
Jonathan Couchman currently manages Affymax, Inc., overseeing a small team of two employees. His background and prior experience are not detailed in the provided information. Further research would be required to determine his specific qualifications and expertise in the biotechnology sector. His role involves managing the company's remaining assets and exploring potential strategic options.
Track Record: Due to the limited information available and the company's current lack of significant operations, it is difficult to assess Jonathan Couchman's track record at Affymax, Inc. His primary responsibility appears to be managing the company's affairs during a period of inactivity. Any strategic decisions or milestones achieved under his leadership would require further investigation.
AFFY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Affymax, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is generally considered to be the most speculative and carries the highest risk for investors. Unlike NYSE/NASDAQ listings, OTC Other stocks often lack the transparency and liquidity associated with exchange-listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to low trading volume.
- Lack of regulatory oversight and transparency.
- Potential for price manipulation and fraud.
- Higher risk of financial distress or bankruptcy.
- Limited access to capital and funding.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Determine the company's capital structure and debt levels.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company was founded in 2001, indicating some history.
- Presence of a CEO/Managing person.
- Previous focus on drug development suggests some expertise.
AFFY Healthcare Stock FAQ
What does Affymax, Inc. do?
Affymax, Inc. previously focused on developing drugs to treat serious and life-threatening conditions. The company operated within the biotechnology sector, aiming to address unmet medical needs through innovative therapies. However, as of the current date, Affymax, Inc. does not have significant operations. The company's historical activities involved research and development of pharmaceutical products, indicating a commitment to advancing healthcare solutions. The company's current state reflects a period of inactivity, suggesting potential challenges in bringing its products to market or a strategic shift in its business direction. The company's evolution from an active drug developer to a company without significant operations underscores the risks associated with the biotechnology sector.
What do analysts say about AFFY stock?
Given Affymax, Inc.'s current lack of significant operations and its listing on the OTC Other tier, there is likely limited to no analyst coverage of the stock. The company's negative profit margin and high beta further contribute to the lack of analyst interest. Investors should rely on their own due diligence and risk assessment when considering an investment in AFFY. Key valuation metrics are not applicable due to the company's lack of revenue and profitability. Growth considerations are speculative and depend on the company's ability to redefine its business strategy and secure funding for new ventures.
What are the main risks for AFFY?
The main risks for Affymax, Inc. include its lack of significant operations, negative profit margin, and high beta, indicating extreme volatility. As an OTC-listed company, AFFY faces additional risks related to limited liquidity, lack of regulatory oversight, and potential for price manipulation. The company's future prospects depend on its ability to redefine its business strategy and secure funding for new ventures, which carries significant uncertainty. Investors should carefully consider these risks before investing in AFFY. The biotechnology sector is inherently risky, with challenges in drug development, regulatory approvals, and commercialization.
What are the key factors to evaluate for AFFY?
Affymax, Inc. (AFFY) currently holds an AI score of 54/100, indicating moderate score. Key strength: Previous experience in drug development.. Primary risk to monitor: Ongoing: Lack of significant operations.. This is not financial advice.
How frequently does AFFY data refresh on this page?
AFFY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AFFY's recent stock price performance?
Recent price movement in Affymax, Inc. (AFFY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Previous experience in drug development.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AFFY overvalued or undervalued right now?
Determining whether Affymax, Inc. (AFFY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AFFY?
Before investing in Affymax, Inc. (AFFY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing and lack of significant operations.
- Disclosure status is unknown, which limits the availability of financial information.